BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine, today announced the appointment of Michael Streit, M.D., M.B.A as the Company’s first Chief Medical Officer (“CMO”).
“We are pleased to welcome Michael to Scorpion at this exciting time in the Company’s evolution, as we shape our first clinical development plans and prepare to submit investigational new drug (“IND”) applications for both of our development candidates, STX-478 and STX-721, in 2023,” said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics. “Michael is an industry veteran with extensive experience in ‘bench to bedside’ oncology drug development. He has also helped advance the field of personalized medicine by developing novel targeted therapies paired with companion diagnostic assays. Over the course of his career, Michael has led clinical studies for innovative medicines including both best-in-class and first-in-class molecules, and he will play a critical role in advancing our broad discovery pipeline into efficient and well-designed clinical trials.”
Dr. Streit brings over 20 years of oncology and clinical development expertise to Scorpion Therapeutics. Prior to joining the Company, he served as Vice President, Senior Global Project Head at Sanofi, where he was responsible for leading the development of SAR444245 (THOR-707), Sanofi’s precisely PEGylated, not-alpha interleukin-2 candidate. Before that, Dr. Streit served in roles of increasing responsibility at GlaxoSmithKline, including Vice President of Development, where he led the development of multiple oncology medicines. Previously, he was a Senior Director at Janssen, where he worked as the early development lead for the company’s prostate cancer and hematology portfolios and supported the Phase 1 development of multiple early development assets. Dr. Streit received his M.D. from the Free University of Berlin and his M.B.A. in International Business from Golden Gate University, San Francisco. He completed a post-doctoral fellowship in at the Cutaneous Biology Research Center at Massachusetts General Hospital.
"I'm thrilled to join the talented team at Scorpion Therapeutics and look forward to advancing the Company’s portfolio of next-generation cancer medicines into the clinic, beginning with its PI3Kα and EGFR Exon 20 programs,” said Dr. Streit. “In preclinical studies, these compounds have demonstrated superior selectivity against well-validated oncogenic drivers, which may enable them to overcome the toxicity issues that limit currently available therapies and deliver superior safety, tolerability and efficacy. I look forward to advancing STX-478 and STX-721, as well as the Company’s more than 15 additional programs, through discovery and clinical development and fulfilling Scorpion’s mission to deliver optimized and transformational therapies to patients living with cancer.”
About Scorpion Therapeutics
Scorpion is a pioneering oncology company redefining the frontier of precision medicine to deliver optimized and transformational therapies for larger populations of patients with cancer, a strategy Scorpion refers to as Precision Oncology 2.0. Scorpion has built a proprietary and fully integrated platform of the most advanced technologies across cancer biology, medicinal chemistry, and data sciences, with the goal of consistently and rapidly creating exquisitely selective small molecule compounds against an unprecedented spectrum of targets. Scorpion aims to leverage its platform to advance a broad pipeline of wholly owned, optimized compounds across three target categories: best-in-class molecules targeting validated oncogene targets; first-in-class molecules for previously undruggable targets; and first-in-class molecules for novel cancer targets. For more information, visit www.scorpiontx.com.
